The Hemoglobinopathy Market is segmented by Indication (Sickle cell disease, Alpha thalassemia, Beta thalassemia), Test Type (Blood Count, Platelet Function, Hemoglobin, Hematocrit), End-Use (Hospitals, Diagnostic Laboratories, Clinics), and Region (North America, Europe, Asia-Pacific, and the Rest of the World).
The Hemoglobinopathy Market is segmented by Indication (Sickle cell disease, Alpha thalassemia, Beta thalassemia), Test Type (Blood Count, Platelet Function, Hemoglobin, Hematocrit), End-Use (Hospitals, Diagnostic Laboratories, Clinics), and Region ...
The Hemoglobinopathy Market is projected to grow from USD 7.3 billion in 2020 to USD 13.2 billion by 2026 at a CAGR of around 10.6% during the forecast period.
Hemoglobinopathy is defined as a genetic disorder that causes structural abnormalities in hemoglobin molecules, particularly defective globin chains. The disease is highly prevalent in Africa, Southeast Asia, and the Mediterranean basin. It can lead to certain other diseases if left untreated such as anemia, organ dysfunction, or death.
Key Players
Key players operating in the Hemoglobinopathy market are-
The growth of the hemoglobinopathy market is primarily driven by the increasing prevalence of sickle cell disease (SCD) and thalassemia. Rising initiatives aimed at creating awareness among consumers regarding the prevalence of sickle cell diseases are likely to drive the market growth further. In addition to this, increasing investment in research and development activities to develop novel therapies is likely to create lucrative opportunities for the players operating in the global hemoglobinopathy market in the coming years.
COVID-19 Impact
The COVID-19 outbreak posed significant challenges across verticals worldwide. It impacted the growth of the hemoglobinopathy market negatively as the therapeutic procedures declined due to fear of coronavirus infection. Also, supply chain disruptions due to the imposition of the lockdown affected the product availability on time and thus, affected the market growth.
Segment Analysis
End-Use Trends
The hemoglobinopathy market has been bifurcated into hospitals, diagnostic laboratories, and clinics. The hospitals' segment accounted for the largest market share in 2020 and is projected to register significant growth during the review period. The segment can be attributed to the presence of established healthcare infrastructure and professional staff.
Regional Analysis
The North American market accounted for the largest market share in 2020 and is projected to grow at a robust CAGR during the review period. This can be attributed to rising consumer awareness and growing emphasis on the adoption of novel therapies to treat sickle cell disease coupled with the presence of key market players such as Abbott Laboratories (US) and Bio-Rad Laboratories, Inc. (US). The market growth in Asia-Pacific is expected to be driven by an increasing number of people suffering from sickle cell disease and thalassemia.
Here is the list of the group of customers that the market hopes to have the greatest opportunity to convert-
Distributors
Suppliers
Manufacturers
Logistics organizations
Government bodies
Report Features
This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.
What deliverables will you get in this report?
Key questions this report answers
Relevant contents in the report
How big is the sales opportunity?
In-depth analysis of the Hemoglobinopathy Market
How lucrative is the future?
Market forecast and trend data and emerging trends
Which regions offer the best sales opportunities?
Global, regional and country level historical data and forecasts
Which are the most attractive market segments?
Market segment analysis and forecast
Which are the top players and their market positioning?
Porter’s five forces analysis, PEST analysis, Life cycle analysis
What are the factors affecting the market?
Drivers & challenges
Will I get the information on my specific requirement?
10% free customization
Research Methodology
This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.
Customization Options
With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:
Company Profiling
Detailed profiling of additional market players (up to three players)
SWOT analysis of key players (up to three players)
Competitive Benchmarking
Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.
Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.
LOADING
LOADING
×
Please enter your contact details. It will allow our analysts to reach out to you.
Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), Danaher Corporation (US), Mindray Medical International Limited (China), Nexcelom Bioscience (US), Nihon Kohden Corporation (Ja-pan), PerkinElmer (US), Siemens Healthineers AG (Germany) and Sysmex Corporation (Japan) are among the key players in the hemoglobinopathy market.
